Rivaroxaban Drops Pro-Coagulation Factor in HF Patients, Johnson & Johnson Researchers Say

November 16, 2009 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

MedPage Today -- ORLANDO -- Biomarkers of hypercoagulability -- ominous signs in patients with heart failure -- appear to be reduced by treatment with the oral, direct Factor Xa inhibitor rivaroxaban, a researcher said here.

Twitter
LinkedIn
Facebook
Email
Print

Johnson & Johnson Family of Companies